31p nuclear magnetic resonance study of the brain in alzheimer’s disease

Journal of Neuropathology and Experimental Neurology

Volumn 47, Issue 3, 1988, Pages 235-248

  Pettegrew, Jay W ^a   Moossy, John ^a   Withers, Gayathri ^a   McKeag, Dennis ^a   Panchaligam, Kanagasabai ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

31P nuclear magnetic resonance; Alzheimer s disease; Membrane lipids; Molecular conformation; Phosphomonoesters; Protein kinase

Indexed keywords

DIAGNOSTIC AGENT; PHOSPHORUS; MEMBRANE LIPID; PHOSPHORUS 31; PROTEIN KINASE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN; BRAIN LEVEL; FEMALE; HUMAN; MALE; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; AUTOPSY; NUCLEAR MAGNETIC RESONANCE; PHOSPHOMONOESTER;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BRAIN; BRAIN CHEMISTRY; FEMALE; HUMAN; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGE; PHOSPHORUS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0023818756     PISSN: 00223069     EISSN: 15546578     Source Type: Journal    
DOI: 10.1097/00005072-198805000-00004     Document Type: Article

References (38)

1. Tomlinson BE, Corsellis JAN. Ageing and the dementias. In: Adams JH, Corsellis JAN, Duchen LW, eds. Greenfield’s neuropathology. Fourth edition. New York: Wiley, 1984:951–1025
2. Terry RD, Hansen LA, DeTeresa R, Davies P, Tobias H, Katzman R. Senile dementia of the Alzheimer type without neocortical neurofibrillary tangles. J Neuropathol Exp Neurol 1987;46: 262–8
3. Ball MJ, Hachinski V, Fox A, et al. A new definition of Alzheimer’s disease: A hippocampal dementia. (Preliminary communications) Lancet 1985;1:14–16
4. Chase TN, Foster NL, Fedio P, Brooks R, Mansi L, Di Chiro G. Regional cortical dysfunction in Alzheimer’s disease as determined by positron emission tomography. Ann Neurol 1984;20(suppl): S170–4
5. Fletcher WA, Sharpe JA. Saccadic eye movement dysfunction in Alzheimer’s disease. Ann Neurol 1986;20:464–71
6. Pettegrew JW, Kopp SJ, Minshew NJ, et al. 31P nuclear magnetic resonance studies of phosphoglyceride metabolism in developing and degenerating brain: Preliminary observations. J Neuropathol Exp Neurol 1987;46:419–30
7. Glonek T, Kopp SJ, Kot E, Pettegrew JW, Harrison WH, Cohen MM. P-31 nuclear magnetic resonance analysis of brain: The perchloric acid extract spectrum. J Neurochem 1982;39:1210–19
8. Cohen MM, Pettegrew JW, Kopp SJ, Minshew N, Glonek T. P-31 nuclear magnetic resonance analysis of brain: Normoxic and anoxic brain slices. Neurochem Res 1984;9:785–801
9. Greiner JV, Kopp SJ, Sanders DR, Glonek T. Organophosphates of the crystalline lens: A nuclear magnetic resonance spectroscopic study. Invest Ophthalmol Vis Sci 1981;21:700–13
10. Barany M, Glonek T. Phosphorus-31 nuclear magnetic resonance of contractile systems. In: Frederiksen DL, Cunningham LW, eds. Methods in enzymology. Volume 85. Structural and contractile proteins. New York: Academic Press, 1982:624–76
11. Pettegrew JW, Kopp S J, Dadok J, et al. Chemical characterization of a prominent phosphomonoester resonance from mammalian brain. 31P and 1H NMR analysis at 4.7 and 14.1 tesla. J Magn Reson 1986;67:443–50
12. Scheibel AB. Dendritic changes in senile and presenile dementias. In: Katzman R, ed. Congenital and acquired cognitive disorders. Based on the proceedings of the 57th Annual Meeting of the Association for Research in Nervous and Mental Diseases held December 2–3, 1977. (Research publication. Volume 57) New York: Raven Press, 1979:107–24
13. Buell SJ, Coleman PD. Dendritic growth in the aged human brain and failure of growth in senile dementia. Science 1979;206:854–6
14. Buell SJ, Coleman PD. Quantitative evidence for selective dendritic growth in normal human aging but not in senile dementia. Brain Res 1981;214:23–41
15. Graveland GA, Williams RS, DiFiglia M. Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington’s disease. Science 1985;227:770–3
16. Zubenko GS, Malinakova I, Chojnacki B. Proliferation of internal membranes in platelets from patients with Alzheimer’s disease. J Neuropathol Exp Neurol 1987;46:407–18
17. Pettegrew JW, Post JFM, Withers G, Panchalingam K. 3IP NMR studies of brain development.(Abstract) Ann Neurol 1986;20:400
18. Dawson RMC. Enzymatic pathways of phospholipid metabolism in the nervous system. In: Eichberg J, ed. Phospholipids in nervous tissues. New York: Wiley, 1985:45–78
19. Pelech SL, Audubert F, Vance DE. Regulation of phosphatidylcholine biosynthesis in mammalian systems. In: Horrocks LA, Kanfer JN, Porcellati G, eds. Phospholipid’s in the nervous system. Volume 2.Physiological roles. New York: Raven Press, 1985:247–58
20. Grundke-Iqbal I, Iqbal K, Tung Y-C, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubule-associated protein τ (tau) in Alzheimer cytoskelet al pathology. Proc Natl Acad Sci USA 1986;83:4913–17
21. Iqbal K, Zaidi T, Wen GY, et al. Defective brain microtubule assembly in Alzheimer’s disease. Lancet 1986;2:421–6
22. Barany M, Chang Y-C, Arus C, Rustan T, Frey WH 2d. Increased glycerol-3-phosphorylcholine in post-mortem Alzheimer’s brain. (Letter) Lancet 1985; 1:517
23. Miatto O, Gonzalez RG, Buonanno F, Growdon JH. In vitro 31P NMR spectroscopy detects altered phospholipid metabolism in Alzheimer’s disease. Can J Neurol Sci 1986;13(Suppl):535–9
24. Bueri JA, Gorell JM, Levine SR, et al. Cerebral phosphate metabolism in Alzheimer and Parkinson dementia measured by 31P NMR spectroscopy. (Abstract) Neurology 1987;37(3 Suppl 1): 160
25. Levine SR, Welch KMA, Helpern JA, Ewing JR, Bruce R, Smith MB. 31P NMR spectroscopic study of multi-infarct dementia. (Abstract) Neurology 1987;37(3 Suppl 1):251
26. Panchalingam K, Post JFM, Pettegrew JW. Evidence for increased aluminum binding ligands in Alzheimer’s disease. A 31IP-27A1 NMR study. (Abstract) Neurology 1987;37(3 Suppl 1):224
27. Glonek T, Burt CT, Barany M. 7 NMR analysis of intact tissue including several examples of normal and diseased human muscle determinations. In: Diehl P, Fluck E, Kosfeld R, eds. NMR basic principles and progress, Volume 19. Berlin: Springer-Verlag, 1981:122–59
28. Candy JM, Klinowski J, Perry RH, et al. Aluminosilicates and senile plaque formation in Alzheimer’s disease. Lancet 1986;1:354–6
29. Crapper DR, Krishnan SS, Dalton AJ. Brain aluminum distribution in Alzheimer’s disease and experimental neurofibrillary degeneration. Science 1973;180:511–13
30. Crapper DR, Krishnan SS, Quittkat S. Aluminum neurofibrillary degeneration and Alzheimer’s disease. Brain 1976;99:67–80
31. Crapper DR, Quittkat S, Krishnan SS, Dalton AJ, De Boni U. Intranuclear aluminum content in Alzheimer’s disease, dialysis encephalopathy and experimental aluminum encephalopathy. Acta Neu- ropathol (Berl) 1980;50:19–24
32. Duckett S, Galle P. Mise en evidence de l’aluminum dans les plaques de la maladie d’Alzheimer: Etudie à la microsonde de Castaing. C R Acad Sci Paris 1976;D-282:393–5
33. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core proteins in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 1985;82:4245–9
34. Perl DP, Brody AR. Alzheimer’s disease: X-ray spectrometric evidence of aluminum accumulation in neurofibrillary tangle-bearing neurons. Science 1980;208:297–9
35. Trapp GA, Miner GD, Zimmerman RL, Mastri AR, Heston LL. Aluminum levels in brain in Alzheimer’s disease. Biol Psychiatry 1978;13:709–18
36. Allinger NL. Conformational analysis. 130. MM2. A hydrocarbon force field utilizing V1, and V2 torsional terms. J Am Chem Soc 1977;99:8127–34
37. Nicoletti F, Wroblewski JT, Iadarola MJ, Costa E. Serine-o-phosphate, an endogenous metabolite, inhibits the stimulation of inositol phospholipid hydrolysis elicited by ibotenic acid in rat hippocampal slices. Neuropharmacology 1986;25:335–8
38. Greenamyre JT, Penney JB, Young AB, D’Amato CJ, Hicks SP, Shoulson I. Alterations in L-glutamate binding in Alzheimer’s and Huntington’s diseases. Science 1985;227:1496–9